AvantGen specializes in the discovery and optimization of novel antibody drugs through its proprietary yeast display technology. This platform leverages a robust yeast display system and a comprehensive Germliner™ Library Collection, which includes over 100 billion fully human antibody clones. The technology allows for the efficient generation of antibodies with desirable properties such as high affinity, specificity, and thermostability. AvantGen's approach is particularly effective for challenging targets, enabling the rapid development of therapeutic, diagnostic, and research tool antibodies. Their capabilities extend to optimizing lead candidates, often improving their binding properties significantly, and generating rabbit monoclonal antibodies that exhibit superior affinity and specificity.

In addition to their yeast display technology, AvantGen has developed a Natural Killer (NK) cell engager platform aimed at enhancing the human innate immune system for cancer immunotherapy. This platform utilizes their extensive antibody library to isolate and develop highly specific, fully human CD16a antibodies. AvantGen's commitment to collaboration is evident in their partnerships with various pharmaceutical and biotech companies, where they provide tailored solutions for antibody discovery and optimization. Their innovative methodologies and collaborative mindset have led to successful projects across multiple therapeutic areas, reinforcing their position as a leader in the biotechnology sector.

United States

AvantGen is a biotechnology company dedicated in accelerating antibody-based therapeutics for their scientific partners by using innovative platforms. Based in San Diego, the fun and collaborative team is steadfast in this pursuit.

AvantGen

Company Details